Evidence map›Paper›PMID 30606201›Full record

ReviewAnnals of clinical microbiology and antimicrobials2019

Prevalence of Acinetobacter baumannii in Saudi Arabia: risk factors, antimicrobial resistance patterns and mechanisms of carbapenem resistance.

Mutasim E Ibrahim

Registry-linked trialAbstract readReview
In one paragraph

Review in Annals of clinical microbiology and antimicrobials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06650384 (Evaluation of the Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid on the Occurrence and Severity of Colistin-Induced Nephrotoxicity in Critically Ill Patients), which is not on this map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06650384 phase2 / phase3completednot on this mapstarted 2024, after this paper: background citation

Evaluation of the Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid on the Occurrence and Severity of Colistin-Induced Nephrotoxicity in Critically Ill Patients

TypeinterventionalSponsorAin Shams UniversityRan2024 to 2026Enrolled180ConditionsNephrotoxicityArmsAddition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin, Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Antibacterial and Immunomodulatory Effects ofInternational journal of molecular sciences · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Prevalence and Resistance Profiles ofAntibiotics (Basel, Switzerland) · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Prevalence and Antibiogram Pattern ofAntibiotics (Basel, Switzerland) · 2025
    Article
  18. Article
  19. Article
  20. Genomic Characterization of Carbapenem-ResistantInfection and drug resistance · 2025
    Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Mutasim E IbrahimDepartment of Basic Medical Science, College of Medicine, University of Bisha, Bisha, Saudi Arabia. mutasimhadi87@hotmail.com.ORCID http://orcid.org/0000-0002-1734-8439

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acinetobacter baumannii is an important opportunistic pathogen due to its capabilities for developing mechanisms of resistance to a wide range of antimicrobial agents including carbapenems. This review described the risk factors, antimicrobial susceptibility and mechanisms of carbapenem resistance of A. baumannii from different geographical regions of Saudi Arabia. Several factors including complexity of intensive care unit (ICU) environments, increased numbers of patients with serious diseases, wide spread gastrointestinal colonization and extensive use of antimicrobial drugs led to a wide prevalence of A. baumannii infections in hospitals in Saudi Arabia. A. baumannii has been noted to be less susceptible to antimicrobials agents, including carbapenems, over time, resulting in the evolution of multidrug-resistant (MDR) strains. Dissemination of MDR A. baumannii is attributed to the extreme use of wide-spectrum antimicrobial drugs in hospitals, cross infection between inpatients, invasive ICU procedures, and hospitalized patients with diabetic and cancer those are under frequent invasive diagnostic and therapeutic interventions. Although an increasing prevalence of colistin and tigecycline resistance has been reported in many hospitals, combinations of these agents with carbapenems or other antibiotics remain the best therapeutic choice and reasonably safe to treat patients with MDR A. baumannii infections. The wide distribution of carbapenem resistant A. baumannii (CRAB) due to several mechanisms with diverse genetic determinants has been documented. Although OXA-23 β-lactamase and OXA-51 β-lactamase are the most common genes responsible for CRAB, other novel genes such as blaVIM, PER-1-like and GES-5 have been discovered in carbapenem resistant strains. The high rates of MDR A. baumannii in Saudi hospitals indicate that extensive investigation into the molecular basis of MDR and developing new therapies of CRAB is needed. Moreover, the development of a local antibiogram database coupled with a nationwide antimicrobial stewardship and infection prevention program might help to improve our knowledge of the resistance patterns of A. baumannii, and in developing a treatment protocol for decreasing the infection burden in Saudi Arabia.

Indexed as

beta-Lactam ResistanceDrug Resistance, BacterialAcinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial Agentsbeta-LactamasesCarbapenemsColistinCross InfectionHospitalsHumansMicrobial Sensitivity TestsPrevalenceRisk FactorsSaudi ArabiaAnti-Bacterial Agentsbeta-lactamase OXA-23beta-lactamase OXA-51, Acinetobacter baumanniibeta-LactamasesCarbapenemsColistinA. baumanniiAntimicrobial susceptibilityCarbapenem resistance mechanismsRisk factorsSaudi Arabia

Identifiers

PMID30606201
PMCPMC6317247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.